How well does your Haemophilia B medical affairs team performance compare with the rest?
According to this latest survey of 100 US haematologists, the performance of haemophilia B medical affairs teams still has a way to go in some key areas before higher satisfaction ratings can be achieved across the board. Find out what physicians think is done well; what they want to see more of; and why some are dissatisfied.
Use Medical Affairs Reputations: Haemophilia B 2017 (US) to discover how your team can better meet the high expectations of physicians at the frontline.
This report compares the current activities of medical affairs teams for six leading haemophilia B treatments from Bioverativ, CSL Behring, Pfizer and Shire. It shows:
It’s time to find out exactly how well your medical affairs team is performing against fierce competition – and establish an action plan to gain competitive advantage.
Interested in the European market? Click here to see the EU5 Edition.
Developed with the help of medical affairs specialists, this report gives you an in-depth comparison of 6 medical affairs teams—answering important questions like:
What do physicians need?
Does your medical affairs team deliver?
What needs improvement?
We surveyed 100 US-based haematologists, chosen from the largest community of validated physicians in the world.
All respondents:
We conducted the survey between November 7-21, 2017.
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
Learn more at www.firstwordgroup.com.
All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved